Board of Directors
Peter Hammond – Chairman
Peter is a managing director of Exto Partners. He has successfully invested in and co-founded more than a dozen companies. In the process he played key leadership roles in the successful commercialisation of many innovative products that are now selling throughout the global market.
With extensive experience in venture capital, strategy and corporate finance, Peter has advised biotechnology, financial services, manufacturing, consumer services and technology companies in Australia and the USA. Peter has assisted companies through a wide range of growth paths and transitions, including early stage financing, the bringing of new products to global markets, and large-scale mergers.
Peter is a member of the Institute of Chartered Accountants and has a B.Bus. from the University of Technology Sydney. He is currently a Director of Exto Partners, Ondek, Sensear, EnVie Fitness, Airtasker, and WhiteSky Labs.
Dr Barry Marshall – Executive Director
Professor Marshall is a world authority on Helicobacter pylori. He is the co-discoverer that H. pylori plays a major causative role in peptic ulcer diseases and co-recipient of the 2005 Nobel Prize for Physiology or Medicine as well as numerous other prestigious awards (including the 1995 Lasker Award). Professor Marshall was elected as a Fellow of the Royal Society in 1999 and the US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discovery has revolutionised the management of peptic ulcer disease, resulting in a cure for peptic ulcers. Related research into a diagnostic test for H. pylori led to a patentable technology and the formation of TriMed Distributors Pty Ltd, a successful private company.
Dr Marshall is the founder of Ondek®. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.
Dr Jenny Harry – Chief Executive Officer
Jenny Harry has 20 years experience in executive management, securing global partnerships, commercialising technologies and raising capital. In her previous role, as CEO and Managing Director of Tyrian Diagnostics (ASX:TDX), Jenny transformed the company from an R&D business to a diagnostics company, and oversaw development of the company’s first diagnostic products through to commercialisation and early revenue generation. Jenny’s corporate experience extends to leading companies in the biotechnology and biopharmaceutical sectors with expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.
Jenny received a PhD in developmental biology from Macquarie University, Sydney, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. In addition to her role as Managing Director at Ondek®, Dr Harry is a non-executive director on several boards, including Chair of QUT Enterprise Holdings Pty Ltd and a non-executive director on the board of ASX-listed Neuren Pharmaceuticals.
Lars Molinder – Non Executive Director
Lars Molinder is currently Senior Adviser to Carnegie Investment Bank in Sweden. He has over 25 years of financial sector experience working solely with companies in the healthcare sector. Lars has been the Head of Medicine and Biotechnology at the Swedish Industrial Development Fund (Industrifonden) and made over 40 investments in early stage companies ranging from medical technology and diagnostics to pharmaceuticals and biotechnology. Prior to joining Carnegie Investment Bank, Lars was the Nordic Head of Healthcare Sector and European co-Head of Healthcare Banking at Alfred Berg and ABN AMRO. Selected recent deals include: advising IPOs of Recipharm, Academedia, Humana, Attendo, Capio, Wilson Therapeutics, Alligator Biosciences, Oncopeptides, Bone Support and BioArctic, all noted on the main list of Nasdaq Stockholm Stock Exchange. Lars has a M.Sc. in Engineering.
Dr Neil Weir – Non Executive Director
Neil is CEO of Sitryx Therapeutics Ltd. Previously he was Senior Vice-President, Discovery UCB S.A., overseeing an integrated portfolio of small molecule and antibody therapeutic projects in the areas of Immunology and Neurology. Neil’s team was responsible for transitioning twenty novel molecules into development, comprising small molecules and antibodies. Neil was one of the inventors of the drug Cimzia®, a novel pegylated anti-TNF. Prior to his role at UCB, Neil was Head of Discovery at Celltech R&D in the UK during which time he was involved in the discovery and development of antibody and antibody fragment-based drugs.
Neil is a member of the Research Directors Group of EFPIA (The European Federation of Pharmaceutical Industries and Associations) and has sponsored three call topics in the European Innovative Medicines Initiative (IMI). He is a member of the MRC Translational Research Group and the HealthTech and Medicines KTN Steering Board, a member of the MRC’s Stratified Medicine Steering Group and chair of the industry advisory panel for UCL vision course for senior executive training for the BioIndustries.
Neil received a BSc (Hons) in biology from Edinburgh University and a PhD at the Institute of Biotechnology (University of Kent at Canterbury) studying metabolic flux through amino acid biosynthesis pathways.
William Jeffrey Veling – Non Executive Director
Dr Jeff Veling is an actively practising medical practitioner in family medicine. He is also involved with medical student teaching. He has a hospital accreditation and up until recently also practised obstetrics. Dr Veling trained in Western Australia.